Search Results

Watch Episode 171 Mentoring in science is more than supervising—it’s about shaping the next generation Mistakes are part of learning—and guiding students through them is more valuable than doing everything

development... seeing if we can bring preclinical models much closer to the actual human experience than Rather than starting with a molecular hypothesis, Serafini’s team noticed that hamsters infected with

With the right lens, you’ll see why efficacy is more than signal strength: it's a fingerprint of conformational

Earlier than many teams do. Modern real-time assays can deliver these insights earlier, faster, and cheaper than most teams assume It’s less bureaucratic than most outsiders think. Why kinetic profiling matters more than most teams realize.

Methods: Rats were divided into sham, sham + Exendin-4 (10 μg/day, i.p), MI, and MI + Exendin-4.

👉 Most biotech founders experience that external conversations consume more energy than they should Each external interaction becomes reactive, shaped more by incoming questions than by strategic intent It becomes an asset that reinforces clarity rather than competing with it. established early Questions move from explanation to evaluation , signaling real engagement rather than Even rejection becomes useful, because it is based on clear criteria rather than confusion. ✅ A biotech

agonist responses to a common reference window Accepting that maximal response may be estimated rather than exact In practice, the precise maximal signal matters less than many assume. EC₅₀ Misconceptions Persist Few misunderstandings derail discovery programs faster than misinterpreting Time Matters More Than Potency For decades, discovery teams prioritized potency above all else.

Less than ~15% of higher plant species, <5% of bacterial and fungal species, and only a fraction of marine This was more than trial-and-error. It was early structure-based pharmacology. Dr. expands drug matter beyond the familiar and encourages deliberate exploration of chemical novelty, rather than

unique ability to combine storytelling, real-world experience, and scientific clarity makes this more than

article GPCR Publication Highlights βCGRP breaks the mold: Distinct signaling patterns reveal it’s more than

.” — Tom Sakmar This makes them more than biomarkers — they’re potential drivers of disease .

For biotech founders, this is more than a presentation problem. It’s a strategic vulnerability. academic interest to practical significance. 3️⃣ Why it’s different ✅ Differentiation must be more than who you’re building for, why now is the right time, and how your solution fits into something bigger than

. 👉 The problem begins when ambition grows faster than structure. This is where the structural tension begins. 👉 Scientific optionality grows faster than strategic capacity And this is where biotech fundraising begins to feel harder than it should.

DiscoverX Partnership — Tools and Insight for GPCR Drug Discovery Modern GPCR discovery depends on more than DiscoverX , a global provider of GPCR assay platforms and translational biology services covering more than

science well, but not the value capture From an investor's perspective, this creates confusion rather than 👉 IP discussions happen earlier in fundraising conversations 👉 Investors look for alignment rather than Biotech fundraising will favor teams that use intellectual property as a tool for clarity rather than

Timeline slips are absorbed as “part of biology” rather than examined as managerial signals. start planning around delays BD and investor messaging drifts Timelines become aspirational rather than

becomes unclear 👉 Capital allocation appears fragmented 👉 The development timeline looks crowded rather than And uncertainty, even when the science is strong, slows biotech fundraising more than most founders expect Saying yes often feels safer than saying no.

. 👉 How long can we operate if fundraising takes longer than expected? visibility fades while the company keeps moving forward , until choices are driven by urgency rather than That shift creates space to act deliberately again, rather than being pushed forward by circumstances

Most GPCR programs don’t fail because of weak molecules—they fail because biology behaves differently than Translate potency and efficacy realistically  → Recognize when deviations reflect biology rather than

By visualizing enzymes as dynamic molecular partners rather than static filters, drug discovery scientists Cytochrome P450: Friend, Foe, and FDA Focus No enzyme class is more important—or more unpredictable—than Yet many discovery teams still relegate them to the “ADME” checklist, rather than the strategic design

Recent studies showed that some AVPR2 mutations could cause biased Gαq/11 protein coupling rather than R68W showed bias to coupling with Gαq/11 protein rather than V162A and wild-type receptor.

GPCR is much more than a podcast? Come check out the brand new Dr.

obvious mistakes , and why preventing that drift requires a different kind of leadership awareness than Founders often sense this as friction rather than failure. Meetings feel heavier. organizationally. 👉 By the time leadership recognizes the gap, correcting course requires far more effort than

The suppressive rather than activating effects of pGRP were confined to blood flow at a high shear rate Blockage of PTK2 or interference of CIB1 no more than slightly affected thrombus formation at a low shear

The science evolves, assumptions break, and timelines shift quietly rather than dramatically. The discovery phase stretches longer than planned. The right ones also know when progress matters more than perfection. 👉 These signals are subtle, but

designed as a continuous learning environment — supporting scientific reasoning as programs mature, rather than Misinterpretation does more than delay progress.

Carola Weiss is a Senior Executive with more than 20 years of international experience in the biopharmaceutical

More than a technical overview, this is a story of curiosity, persistence, and using science to meet Rather than being discouraged by challenges, he views them as forcing functions for creativity and growth

This time with none other than Dr. Bryan Roth There are 10 open tickets available. Get yours now!

The move comes less than three weeks after X4 pulled together a $55 million PIPE and amended a loan facility